Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Which blood-based biomarkers are closest to clinical implementation in stroke care?

Gerrit M. Grosse • 22 Oct 2026
WSC 2026
Stroke
MOSES

Gerrit M. Grosse, MD, PhD, University Hospital Basel, Basel, Switzerland, comments on the potential of blood-based biomarkers in stroke care, highlighting MR-proANP as a marker of atrial dysfunction associated with cardioembolic stroke. Dr Grosse speaks about the MOSES trial (NCT03961334), which is ongoing to assess this biomarker. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gerrit M. Grosse

Biomarkers of plaque vulnerability in stroke: causality and emerging imaging and blood biomarkers
3:11
Biomarkers of plaque vulnerability in stroke: causality and emerging imaging and blood biomarkers
Gerrit M. Grosse • 22 Oct 2026
Thrombus-based inflammatory gene expression profiles to identify etiology of stroke
1:13
Thrombus-based inflammatory gene expression profiles to identify etiology of stroke
Gerrit M. Grosse • 21 May 2025
The role of inflammatory biomarkers in secondary stroke prevention
2:03
The role of inflammatory biomarkers in secondary stroke prevention
Gerrit M. Grosse • 21 May 2025

Related Videos

Granular hypoperfusion intensity ratio: a novel perfusion metric for infarct growth in stroke
1:51
Granular hypoperfusion intensity ratio: a novel perfusion metric for infarct growth in stroke
Giorgio Busto • 21 Oct 2026
Infarct growth rate in acute ischemic stroke: measuring fast vs slow progressors
2:25
Infarct growth rate in acute ischemic stroke: measuring fast vs slow progressors
Giorgio Busto • 21 Oct 2026
Biomarkers of plaque vulnerability in stroke: causality and emerging imaging and blood biomarkers
3:11
Biomarkers of plaque vulnerability in stroke: causality and emerging imaging and blood biomarkers
Gerrit M. Grosse • 22 Oct 2026
How is AI changing acute stroke treatment decisions, and what evidence is missing?
2:30
How is AI changing acute stroke treatment decisions, and what evidence is missing?
Aravind Ganesh • 22 Oct 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals